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Abstract
Purpose of Review Apolipoprotein C-III (apoC-III) is known to inhibit lipoprotein lipase (LPL) and function as an important
regulator of triglyceride metabolism. In addition, apoC-III has also more recently been identified as an important risk factor for
cardiovascular disease. This review summarizes the mechanisms by which apoC-III induces hypertriglyceridemia and promotes
atherogenesis, as well as the findings from recent clinical trials using novel strategies for lowering apoC-III.
Recent Findings Genetic studies have identified subjects with heterozygote loss-of-function (LOF) mutations in APOC3, the
gene coding for apoC-III. Clinical characterization of these individuals shows that the LOF variants associate with a low-risk
lipoprotein profile, in particular reduced plasma triglycerides. Recent results also show that complete deficiency of apoC-III is not
a lethal mutation and is associated with very rapid lipolysis of plasma triglyceride-rich lipoproteins (TRL). Ongoing trials based
on emerging gene-silencing technologies show that intervention markedly lowers apoC-III levels and, consequently, plasma
triglyceride. Unexpectedly, the evidence points to apoC-III not only inhibiting LPL activity but also suppressing removal of
TRLs by LPL-independent pathways.
Summary Available data clearly show that apoC-III is an important cardiovascular risk factor and that lifelong deficiency of
apoC-III is cardioprotective. Novel therapies have been developed, and results from recent clinical trials indicate that effective
reduction of plasma triglycerides by inhibition of apoC-III might be a promising strategy in management of severe hypertriglyc-
eridemia and, more generally, a novel approach to CHD prevention in those with elevated plasma triglyceride.
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Introduction
Apolipoprotein C-III (apoC-III), a small protein (79 amino acid
residues) that contains two amphipathic helices [1], was dis-
covered almost 50 years ago but until it was recognized as an
important risk factor for cardiovascular disease (CVD) did not
attract much attention. It resides on circulating lipoproteins
including high-density lipoproteins (HDL), low-density lipo-
protein (LDL), and triglyceride-rich lipoproteins (TRLs) such
as chylomicrons (CM) and very low density lipoprotein
(VLDL). Today, we know that apoC-III is a multifaceted pro-
tein with major physiological relevance. It not only regulates
triglyceride metabolism but also is believed to participate in
pathological processes involved in atherosclerosis.
Role of ApoC-III Biology in the Human
Pathophysiology of CVD
The structure and function of apoC-III have been studied for
many years but we still do not have a clear picture of its many
interactions with lipoprotein particles, other apolipoproteins,
lipolytic enzymes (such as LPL), and cell surface receptors
[1–4]. It has long been known that, as with other small apoli-
poproteins, apoC-III binds to the surface of lipoproteins by
virtue of being able to form amphipathic helices along the
peptide chain, and recent results indicate that aromatic
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residues in the C-terminal half of apoC-III are especially im-
portant in mediating binding to TRLs [5]. The protein un-
dergoes posttranslational modification resulting in three dif-
ferent isoforms containing zero, one, or two sialic acids
(termed apoC-III0, apoC-III1 and apoC-III2) [6]. The physio-
logical relevance of these glycoforms is still unclear, but the
degree of sialylation of apoC-III has been proposed to influ-
ence lipoprotein lipase (LPL)-mediated hydrolysis of TRLs in
the circulation. Recent investigations reveal that the different
apoC-III glycoforms show specific patterns over the range of
total apoC-III concentration, but the impact of this variation
on the atherogenic potential of the apoprotein is unclear [7•].
ApoC-III is a key regulator of triglyceride metabolism,
and human kinetic studies have shown that impaired catab-
olism of TRLs, linked to increased levels of plasma apoC-
III, is the main determinant of plasma triglyceride levels in
the population [8]. In accord with this concept, metabolic
studies in hypertriglyceridemic subjects have demonstrated
that apoB-containing lipoproteins are removed significantly
less efficiently from the circulation if they are enriched in
apoC-III [9]. It remains to be clarified if the impaired re-
moval of TRLs and their remnants is mainly due to reduced
lipolytic capacity or to reduced hepatic removal of TRL
remnants. ApoC-III has also been proposed to directly in-
fluence plasma triglycerides by enhancing hepatic VLDL
secretion [10–12]. Studies in genetically modified mice
overexpressing apoC-III displayed increased hepatic secre-
tion of VLDL particles [10]. However, inhibition of apoC-
III synthesis using antisense oligonucleotides (ASO) in
mice did not reduce VLDL secretion [13], so the biological
significance of apoC-III as a regulator of hepatic VLDL
assembly and release is still unclear, particularly in humans.
A further illustration of this point comes from recent inves-
tigation of VLDL metabolism in subjects heterozygous for
apoC-III deficiency. Here, individuals with half the level of
apoC-III had the same VLDL apoB production rate as their
unaffected siblings (who had normal apoC-III levels and
higher plasma triglyceride) [14•].
There are several potential mechanisms whereby apoC-III
can induce increased plasma triglycerides and accumulation
of TRL remnant particles. These include inhibition of LPL-
mediated lipolysis of TRLs, and impaired removal of TRL
remnants (Fig. 1).
Inhibition of LPL-mediated lipolysis of TRLs—ApoC-III is
a known inhibitor of lipoprotein lipase (LPL), the main en-
zyme responsible for the hydrolysis of triglyceride in TRLs.
Underlying mechanisms include inhibiting TRL binding to
the negatively charged cell surface where the enzyme is resi-
dent [16] and inhibiting activation of the enzyme by
displacing the LPL activator apoC-II from the surface of the
TRL particle [17]. This displacement is likely due to compe-
tition for available binding sites on the phospholipid mono-
layer surface of the lipoprotein; apoC-III is the most abundant
apolipoprotein present at an average of 25–50 molecules per
VLDL particle [18, 19].
Preventing clearance of lipoprotein remnants—Remnant
particles, formed by partial lipolysis of TRLs, are rapidly re-
moved from the circulation by the liver. The mechanism in-
volves binding of remnants to heparan sulfate proteoglycans
(HSPGs) and to members of the LDL receptor family on he-
patocytes, followed by endocytosis. The ligand on the rem-
nant particles is apolipoprotein E (apoE), and by displacing
this protein from the lipoprotein particle surface (in analogy to
the action on apoC-II above) [18], apoC-III can effectively
impair the clearance of remnants [20]. Thus, the ratio of
apoC-III (with its inhibitory role) and apoE (which mediates
particle receptor-mediated clearance) on the remnant surface
is potentially an important regulator of the metabolism of
these lipoproteins [18].
In addition to effects on lipid metabolism, apoC-III has
been shown to directly influence development of atheroscle-
rosis by several routes including facilitating subendothelial
accumulation of atherogenic lipoproteins by increasing their
affinity for artery wall proteoglycans [21–26]. Themechanism
of this interaction is complex since apoC-III itself does not
bind artery wall proteoglycans, but seems to provoke changes
in the lipid composition of the lipoproteins leading apoB to
adopt a conformation that is more favorable for proteoglycan
binding [23, 27]. ApoC-III may also promote aggregation and
fusion of retained lipoproteins in the artery wall by activating
sphingomyelinases (SMase) [28•, 29•]. In addition, apoC-III
has been reported to facilitate interaction between monocytes
and endothelial cells, promote smooth muscle cell prolifera-
tion, and induce inflammation by activating adhesion mole-
cules and the proinflammatory nuclear factor-κB in mono-
cytes and endothelial cells [30, 31].
Lessons from Genetic Studies: Why Lowering
of apoC-III Inhibition Should Be Pursued
Recent data from exome-wide association studies of lipids in
> 300,000 individuals demonstrated a causal relationship be-
tween genetically determined elevated plasma triglyceride
levels and coronary artery disease (CAD) [32•, 33•, 34]. The
studies also provided evidence for the concept that increased
lipolysis (i.e., LPL activity) may lead to reduced risk of ath-
erosclerosis. Earlier success in demonstrating the impact on
CAD risk of PCSK9 LOF mutations that led to LDL lowering
paved the way for an examination of the consequences of LOF
mutations of the apoC-III gene, and control of apoC-III as a
prime lipid-lowering target [35]. The concept has also stimu-
lated interest in other proteins that regulate lipolysis of TRLs
including apoA-V and the Angptl family as alternate, novel
therapeutic strategies.
Pollin et al. reported in 2008 that carriers of the APOC3
null mutation (R19X) had about 40% lower plasma apoC-III
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levels than non-carriers, significantly lower postprandial tri-
glycerides, and higher HDL-cholesterol levels [36]—the
R19X variant inserts a premature stop-codon in the mRNA
transcript of themutated gene [36]. As a non-invasivemeasure
of prevalent atherosclerosis, the coronary artery calcification
(CAC) score was determined in 1033 Amish subjects (repre-
sentative of the background population in which the variant
was found) and heterozygote carriers of the R19X null muta-
tion. The latter had CAC scores significantly lower than non-
carriers, and the authors therefore suggested that lifelong de-
ficiency of apoC-III is cardioprotective [36]. This null variant
was also reported to be associated with low plasma levels of
apoC-III and triglycerides in a separate cohort on the island of
Crete, with a frequency of about 2% [37•]. The allele frequen-
cy of the R19X variant is rare in the general population; 0.08%
in Americans [38] and 0.05% in Europeans [39]. Recently,
Reyes-Soffer reported that the 50% lower plasma apoC-III
and 35% lower plasma triglyceride levels in R19X variant
carriers were due to markedly higher clearance rates for
VLDL particles indicating a faster lipolytic rate [14•]. As ex-
pected, the carriers of the R19X variant had lower apoC-III
production rate but also increased apoC-III clearance rate. In
this metabolic investigation, no influence of relative apoC-III
deficiency was observed on direct VLDL clearance [14•].
The favorable lipid profile with low triglycerides and high
HDL-cholesterol in subjects with APOC3 LOF mutations has
been validated in a cohort (n = 80) recruited on the basis of
high HDL-cholesterol levels (> 95th percentile) [40]; in 5 out
of the 80 individuals, heterozygote LOF mutations in APOC3
(c.-13-2A > g, C.55 + 1G >A and Ala43Thr) were identified
[40]. Thus, APOC3mutations are enriched in individuals with
hyperalphalipoproteinemia. The Ala43Thr variant has also
been reported to associate with low apoC-III and plasma tri-
glycerides in three individuals of Yucatan Indian descent [41].
Despite the findings quoted above from human turnover stud-
ies [14•], there are continued hints that enhanced lipolysis
might not be the only mechanism for the lower plasma triglyc-
erides in individuals with APOC3 LOF mutation, as
Suddaram et al. reported that the Ala43Thr variant induces
an impaired lipidation of nascent VLDL particles during the
assembly of VLDL in the liver [42].
Two landmark studies published back-to-back in the New
England Journal of Medicine in 2014 provided concrete evi-
dence that apoC-III LOF variant carriers exhibit marked re-
ductions in apoC-III, have lower plasma triglycerides, and
experience significantly fewer CVD outcomes [43•, 44•].
These results were based on LOF mutations: the R19X non-
sense mutation, two splice-site mutations (IVS2 + 1G→A
and IVS3 + 1G→ T), and the Ala43Thr missense mutation.
The association of LOF carrier status with CVD outcomes
was established independently in the NHLBI Exome
Sequencing Project (n = 110,970) and in the Copenhagen
Study (n = 75,725) [43•, 44•]. The fact that these large cohort
studies show such similar results strengthens the findings con-
siderably. Reduction in plasma triglycerides in both studies
was about 40% in carriers compared to non-carriers, and this
lipid difference was associated with marked reductions of
CVD risk (approximately 40%) in both studies. These results
suggest that 1 mg/dl decrease in apoC-III translates to a 4%
decrease in CVD incidence [43•].
Recently, the power of LDL cholesterol and remnant cho-
lesterol to predict ischemic vascular disease (IVD) risk was
Fig. 1 Proatherogenic action of apoC-III on lipid metabolism and
atherogenicity. The APOC3 expression in hepatocytes is regulated by
many metabolic and nutritional components, including circulating
glucose, insulin, and fatty acids [15•]. Glucose induces increased
expression of APOC3 via activation of the carbohydrate response
element-binding protein (ChREBP) and hepatic nuclear factor-4a
(HNF4a). Also, dietary intake of saturated fatty acid levels increased
APOC3 expression by activation mainly of the peroxisome proliferator-
activated receptor (PPAR) γ coactivator-1 β (PGC-1β). Insulin and
dietary intake of polyunsaturated fatty acid (PUFA) represses by
promoting phosphorylation of the nuclear transcription factor forkhead
box O1 (FOXO1). Increased APOC3 expression induces increased
plasma apoC-III concentration. ApoC-III induces increased plasma
triglycerides and accumulation of triglyceride-rich lipoprotein (TRL)
remnant particles by several mechanisms. These include inhibition of
lipoprotein lipase (LPL)-mediated lipolysis of TRLs and preventing
hepatic clearance of lipoprotein remnants. ApoC-III also exerts strong
atherogenic functions through both indirect and direct mechanisms.
These include increasing affinity of atherogenic lipoproteins to the
extracellular matrix of the artery wall, leading to increased
accumulation of atherogenic lipoproteins in the artery wall, and by
promoting proinflammatory responses in endothelial cells and monocytes
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examined in apoC-III LOF carriers in a meta-analysis of
137,895 individuals [45]. The data demonstrated that the re-
duction of IVD risk in heterozygote carriers of apoC-III LOF
mutations associated with reduction of remnant cholesterol
(mean of − 43%) but not with change in LDL cholesterol
(mean of − 4%) [45]. Apolipoprotein B, a marker of the total
number of atherogenic lipoprotein particles in the
circulation—each of VLDL, remnants, and LDL contains
one apoB protein per particle—was 13% lower in LOF het-
erozygotes compared to non-carriers. In this context, it is note-
worthy that in a recent evaluation of the association of the
plasma triglyceride with CVD risk, Ference et al. [46•] report-
ed, on the basis of large-scale Mendelian randomization anal-
yses, that genetically determined change in triglyceride was
not associated with altered CVD risk unless there was an ac-
companying perturbation in circulating apoB (i.e., particle)
levels.
As these LOF mutations are rare, none of the early studies
reported homozygosity of apoC-III LOF despite that fact that
about 200,000 participants were examined. However, four
individual homozygotes for the Arg19Thr mutation in apoC-
III were recently identified in the PROMIS study which in-
cluded 10,503 Pakistan participants [47•]. One of the LOF
homozygote probands, his wife, and 27 first-degree relatives
were invited for further investigations and genotyping.
Unexpectedly, the wife also was found to be a LOF homozy-
gote and, consequently, all nine children in the family were
homozygotes for the Arg19Thr APOC3 variant [47•]. The
plasma concentrations of apoC-III were extremely low in all
homozygote family members as compared to heterozygotes
and non-carriers. Fat feeding was used as a challenge to eval-
uate triglyceride metabolism in this condition; compared to
non-carriers, homozygote family members showed a marked-
ly blunted postprandial triglyceride elevation [47•]. These
studies demonstrate critically that complete deficiency of
apoC-III is not lethal, and that it is associated with very rapid
lipolytic rates for TRLs.
Can Dietary Modulation Reduce Plasma apoC-III
Levels?
Glucose is known to modulate the hepatic expression of key
enzymes of the glycolytic and lipogenic pathways [48], and
Caron et al. have shown that glucose induces APOC3 expres-
sion in hepatocytes in vitro via a mechanism involving the
transcription factors carbohydrate response element-binding
protein and hepatocyte nuclear factor-4α [49] (Fig. 1).
Interestingly, insulin and glucose seem to have opposite ef-
fects on apoC-III expression in human hepatocytes [49–51]. It
has therefore been hypothesized that in insulin resistance as-
sociated with hyperglycemia, as in type 2 diabetes, insulin no
longer represses APOC3 expression, whereas chronic glucose
elevation enhances APOC3 expression, leading to increased
plasma apoC-III levels and increased risk for atherosclerosis,
via either induction of hypertriglyceridemia or other vascular
effects of apoC-III [30, 52]. Thus, the influence of diets on
cardiometabolic risk factors including apoC-III may differ de-
pending on metabolic status. This and the fact that most die-
tary studies are small with different designs and dietary inter-
ventions may explain the inconsistent results presented [53].
That said, a large number of studies seem to indicate that diets
enriched in carbohydrates (CHO) correlate with higher plasma
apoC-III levels [54–58]. For example, high consumption of
fructose induces adverse effects on cardiometabolic risk fac-
tors including increased plasma apoC-III levels [59, 60].
Fructose restriction, on the other hand, has been reported to
reduce apoC-III concentrations [60, 61]. In line with these
observations, we recently reported that a short-term interven-
tion using an isocaloric low-carbohydrate diet induced a rapid,
robust, and significant decline of apoC-III concentrations in
addition to other metabolic benefits in obese subjects with
NAFLD [62•].
Consumption of saturated fat seems to increase plasma
apoC-III levels [63, 64] (Fig. 1). In contrast, dietary intake
of mono- and unsaturated fat appears to reduce apoC-III con-
centrations [64]. Dietary intake of marine oils and omega-3
fatty acid preparations is linked to small, yet statistically sig-
nificant improvements in lipoprotein profile of which the
strongest effect is on plasma triglyceride concentration.
Across studies, this effect was dose-dependent and related to
studies’ mean baseline triglyceride [65]. Recent reports indi-
cate that omega-3 PUFAs significantly decrease apoC-III [66•,
67•], and this may be a mechanism for their triglyceride-
lowering effects [68]. In summary, available data are still in-
consistent but dietary intervention may be used to reduce
apoC-III concentrations; however, more research is needed.
Available Therapies Reducing ApoC-III Plasma
Concentrations
Both in vitro and animal studies indicate that fibrates as per-
oxisome proliferator-activated receptor alpha (PPARα) ago-
nists reduce APOC3 expression resulting in lowering of plas-
ma triglyceride [69–71]. In contrast, overexpression of human
APOC3 in transgenic mice is associated with hypertriglyc-
eridemia [72]. The underlying molecular mechanisms for
how PPARα agonists influence APOC3 expression remain
to be fully elucidated but seem to include a role for various
co-factors that alter the PPAR-mediated transcriptional activa-
tion of target genes via complex signaling pathways [73]. The
efficacy of different fibrates in lowering plasma triglyceride
levels has been reported to be linked to their ability to reduce
APOC3 expression in hepatocytes [74]. Overall, the response
in APOC3 expression to fibrates is variable and depends on
the agents’ efficacy and selectivity.
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Surprisingly, no data exist on the responses of apoC-III levels
in fibrate intervention trials [the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) trial; the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial; the
Bezafibrate Infarction Prevention (BIP) trial; and the Veterans
Affairs High-Density Lipoprotein Cholesterol Intervention Trial
(VA-HIT)] addressing associations between CVD outcomes and
changes in lipid profiles. Available data on changes of apoC-III
levels are sparse and mainly from smaller studies with short
duration and variable design, or from post hoc analyses. The
reduction of apoC-III on fibrates in clinical studies seems to
average about 20%, but there is a wide range from 10 to 40%
[75–79]. Data on how PPARγ agonists (pioglitazone,
rosiglitazone) affect apoC-III metabolism in humans are even
scantier and partially conflicting as pioglitazone seems to reduce
plasma apoC-III levels whereas rosiglitazone appears to have
the opposite effect [80, 81].
Interestingly, there is robust evidence to indicate that both
nicotinic acid (niacin) and statin therapy can reduce hepatic
APOC3 expression. Hernandez et al. reported that the perox-
isome proliferator-activated receptor gamma coactivator 1-
beta (PGC-1β), a transcriptional cofactor, regulates the ex-
pression of APOC3 [82]; nicotinic acid has been shown to
reduce PGC-1β expression and this leads in turn to a decrease
in APOC3 expression. In human kinetic studies, Ooi et al.
reported that rosuvastatin not only decreased the production
rate of apoC-III but also increased its catabolism resulting in a
reduced VLDL-apoC-III concentration [83]. In accord with
these mechanistic linkages, plasma apoC-III levels were found
to be significantly reduced by statins in a meta-analysis of
well-controlled clinical trials [84].
Omega-3 carboxylic acids (OM3-CA) have been shown to
reduce plasma apoC-III relative to placebo, as well as apoC-III
in HDL, and apoC-III in LDL [67•, 85, 86]. Unexpectedly,
OM3-CA selectively also increase the concentration of LDL
that does not contain apoC-III, a subspecies with, reportedly, a
weak relation to coronary heart disease [67•]. In line with
these findings, a recent meta-analysis (n = 2062) reported that
omega-3 PUFA in doses > 2 g for 7 days was associated with
significant reductions of apoC-III levels [66, 87]. The reduc-
tion of apoC-III varied between 20 and 30%. However, it
remains to be proven if the apoC-III reduction is replicated
in the recently published REDUCE-IT and VITAL trials, or
indeed is found to contribute to clinical benefit [88, 89].
Pipeline Options Targeting for ApoC-III Inhibition
As apoC-III has emerged as an attractive target, several novel
technologies have been devised to regulate its concentration in
cells and in the circulation. These include small antisense oli-
gonucleotides (ASOs), interfering RNAs (siRNAs), and mono-
clonal antibodies [90, 91]. RNA interference and related RNA
silencing techniques provide unprecedented opportunities to
control gene expression in vivo [92], as they selectively silence
translation of their target messenger RNAs [93, 94].
The translation of these silencing technologies from basic
science laboratories to the clinic has been speedy. Several
discoveries have underpinned this phenomenon; of particular
importance is the development of novel targeting strategies.
For example, binding GalNAc moieties—the ligand of the
hepatic asialoglycoprotein receptor—to siRNA or ASO [95,
96] enables efficient RNAi-mediated gene silencing to occur
specifically in hepatocytes and enhances the potency of the
agents about 30-fold [97]. Again, PCSK9 inhibition has been
a pathfinder in this new lipid-lowering therapeutic approach.
Inclisiran, a subcutaneously administered investigational
RNAi therapeutic (ALN-PCSsc), targeting PCSK9 for the
treatment of hypercholesterolemia successfully lowers LDL
over the long term and is presently in phase III development.
Volanesorsen (IONIS-APOCIII Rx) represents a second-
generation antisense nucleotide designed to specifically bind
to apoC-III mRNA. Volanesorsen was reported to reduce ef-
fectively APOC3 expression and plasma triglycerides in ro-
dent models and nonhuman primates [13]. The phase I clinical
study was a double-blind placebo-controlled, dose-ranging
study in 25 healthy subjects. It showed a dose-dependent re-
duction of apoC-III of up to 90% and concomitant marked
reduction in plasma triglycerides. Likewise, volanesorsen re-
sulted in marked reduction of plasma triglycerides by 56 to
86% in three patients with familial chylomicron syndrome
(FCS) with triglycerides ranging from 15.9 to 23.5 mmol/l
due to genetic defects in LPL [98•]. The reduction of apoC-
III varied from 71 to 90% after 13 weeks of the therapy, and,
importantly from a clinical efficacy point of view, all three
patients had plasma triglycerides less than 5.7 mmol/l after
the therapy thereby diminishing considerably the risk of pan-
creatitis. These dramatic results strongly indicate that apoC-III
not only inhibits LPL activity but has a suppressive action on
the overall removal of TRLs by LPL-independent pathways.
Further evidence was provided in murine studies using an
apoC-III ASO showing that apoC-III inhibits the hepatic
clearance of TRLs by the LDLR/LRP1 pathways [99•]. The
seminal role of these LPL-independent pathways was con-
firmed by further studies in subjects with LPL deficiency
[100].
These proof-of-concept studies were followed by a rapid
initiation of phase II dose-ranging trials using volanesorsen as
a monotherapy or as an add-on to stable fibrate therapy for
13 weeks [101•]. This cohort (n = 57) included untreated pa-
tients with a wide range of plasma triglycerides (from 4.0 to
22.6 mmol/l). The results showed that decreases of both plas-
ma apoC-III and triglycerides were dose-dependent, averag-
ing about 80% and 71% respectively. The simultaneous in-
crease of HDL-cholesterol was about 46%. Volanesorsen was
also tested in a randomized, double-blind, placebo-controlled
trial in 15 overweight or obese subjects with type 2 diabetes
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[102]. Patients had HbA1c > 7.5% on a stable dose of metfor-
min (> 1000 mg/day) and plasma triglycerides between 200
and 500 mg/dl and were randomized in a 2:1 ratio to receive
volanesorsen 300 mg or matched placebo for 15 weekly
doses. Volanesorsen markedly improved dyslipidaemia by re-
ducing both apoC-III (− 88%) and plasma TG (− 69%) and
increased HDL-cholesterol by 42% after 13 weeks. Notably,
the plasma triglyceride level averaged 2.8 mmol/l (249 mg/dl)
at baseline, and all patients achieved levels below 0.84mmol/l
(< 76 mg/dl) at the end of the treatment period. A two-step
hyperinsulinemic-euglycemic clamp was performed before
and after the treatment period, and it was found that
volanesorsen improved whole-body insulin sensitivity by
about 57% as compared to placebo. The investigators reported
a significant relationship between improved insulin sensitivity
and plasma apoC-III suppression. Notably, HbA1c signifi-
cantly improved during the volanesorsen treatment. These da-
ta suggest that effective suppression of plasma triglycerides by
inhibition of apoC-III might be a promising strategy in man-
agement of diabetic dyslipidaemia.
Two randomized, double-blind, placebo-controlled phase 3
trials with volanesorsen have been performed. In the
APPROACH trial, 66 patients with documented FCS and with
fasting triglycerides > 8.5 mmol/L (750 mg/dl) on restricted
low-fat diet were randomized to receive either active drug
300 mg once a week or matched placebo for 52 weeks
[103]. In the COMPASS study which recruited 113 subjects
with severe hypertriglyceridemia between 5.7 and 14.8 mmol/
l (500–1261 mg/dl) [90], patients were randomized in a 2:1
ratio to receive either volanesorsen or placebo once weekly for
26 weeks. In both studies, the efficacy of volanesorsen to
reduce both apoC-III and triglyceride concentrations was re-
markable, averaging about 70–80%. As severe hypertriglyc-
eridemia associates with high risk of acute pancreatitis, the
data from the two studies were combined to clarify if
volanesorsen therapy can lower the risk of this serious condi-
tion [104]. The episodes of acute pancreatitis were markedly
less in patients treated with active drug than in the placebo
group.
Despite the fact that FCS is a severe disorder and there are
no approved drugs to prevent the attendant high risk of pan-
creatitis, the FDA did not approve volanesorsen for the treat-
ment of FCS as a rare disease (August 2018) [105]. However,
in March 2019, the Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency
(EMA) adopted a positive opinion recommending conditional
marketing authorization for Waylivra (volanesorsen) as an ad-
junct to diet in adult patients with genetically confirmed FCS
who are at high risk for pancreatitis, in whom response to diet
and triglyceride-lowering therapy has been inadequate.
To complete this therapeutic overview, it should be noted
that apoC-III (again like PCSK9) can also be targeted by
monoclonal antibodies, and it has been proposed that anti-
apoC-III monoclonal antibodies would prevent binding of
apoC-III to lipoproteins resulting in enhanced clearance of
lipoprotein-free apoC-III via the kidney [106•].
Safety Concerns of ApoC-III Inhibition by Antisense
Oligonucleotide Therapy
The negative decision by FDA to approve volanesorsen for
the treatment of FCS as a rare disease was based on safety
concerns. Data from phase II–III clinical studies indicated that
volanesorsen therapy was well tolerated overall with major
side effects being local reactions at injection sites; the inci-
dence of these varied between 10 and 23%, and they were in
general mild to moderate and resolved rapidly. More impor-
tant was the occurrence of thrombocytopenia and resulting
potential for serious bleeding that was reported in the
APPROACH study. Grade 4 thrombocytopenia occurred in
three patients, which ended after they stopped taking the drug.
None of these patients had any major bleeding events, and all
recovered to normal platelet count following drug discontinu-
ation and administration of corticosteroids. Furthermore, there
were no withdrawals due to platelet counts after the company
began monitoring the side effect. In contrast, no significant
reduction of platelet counts was reported in the COMPASS
study [15•, 95], and current thinking is that underlying mech-
anism seems to be linked to the drug delivery methodology
and not to apoC-III per se, as another 2′-MOE modified anti-
sense oligonucleotide has been reported to cause dose-
dependent reduction of platelets in monkeys and humans
[107]. These potential issues may be addressed by the conju-
gation of GalNAc to ASO targeting apoC-III which as men-
tioned above enables liver-specific delivery of the anti-apoC-
III ASO and enhanced potency allowing lower doses to be
used [95, 108]. Pilot data in healthy volunteers have shown
that IONIS-APOCIII LRx, a GalNAc3 conjugated APOC3
antisense oligonucleotide, has comparable potency to
volanesorsen to lower both plasma apoC-III and TG levels,
but without significant side effect or platelet reduction [109].
Results seem promising, but whether the safety and tolerabil-
ity will be improved in larger clinical studies remains to be
demonstrated.
Conclusions
Overall, the available data suggest that the lowering of apoC-
III and associated change in plasma triglycerides and remnant
cholesterol can be protective against progression of athero-
sclerosis reflected in reduced CVD risk. Consequently, the
inhibition of apoC-III synthesis and reduction of plasma
apoC-III levels has become an attractive therapeutic target to
reduce the residual risk in statin-treated subjects. The future
will evidence if the translation of current “bench” knowledge
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on apoC-III pathophysiology to “bedside” will be as rapid as
for the development of PCSK9 inhibitors; will apoC-III be the
next PCSK9?
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